The Online Investor

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Wed., Feb. 26, 5:45 PM

Slide #94. Foamix Pharmaceuticals Ltd Menlo Therapeutics Inc.

Acquirer: Foamix Pharmaceuticals Ltd (FOMX)
Acquiree: Menlo Therapeutics Inc. (MNLO)
Details: Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and stockholder proposals necessary to complete the previously announced merger at their respective shareholder / stockholder meetings held earlier today. Pending the expiration of a 30-day waiting period required by Israeli law and satisfaction of closing conditions set forth in the merger agreement between Foamix, Menlo and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of Menlo, Menlo's merger subsidiary will merge with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo.

Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing Co.'s proprietary topical drug candidates for dermatological therapy. Co.'s main product candidate, FMX101 (4% minocycline foam), is being developed for the treatment of moderate-to-severe acne and its second product candidate, FMX103 (1.5% minocycline foam), is being developed for the treatment of moderate-to-severe papulopustular rosacea. Both product candidates are topical foam formulations of the antibiotic minocycline and were developed using its Molecule Stabilizing Technology, a proprietary foam platform designed to optimize the topical delivery of minocycline.

Open the FOMX Page at The Online Investor »

Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing Co.'s proprietary topical drug candidates for dermatological therapy. Co.'s main product candidate, FMX101 (4% minocycline foam), is being developed for the treatment of moderate-to-severe acne and its second product candidate, FMX103 (1.5% minocycline foam), is being developed for the treatment of moderate-to-severe papulopustular rosacea. Both product candidates are topical foam formulations of the antibiotic minocycline and were developed using its Molecule Stabilizing Technology, a proprietary foam platform designed to optimize the topical delivery of minocycline.

Open the MNLO Page at The Online Investor »

Company Name: 
Foamix Pharmaceuticals Ltd.
Website: 
www.foamix.co.il
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding FOMX: 
4
Total Market Value Held by ETFs: 
$2.17M
Total Market Capitalization: 
$247.00M
% of Market Cap. Held by ETFs: 
0.88%
Company Name: 
Menlo Therapeutics Inc
Website: 
www.menlotherapeutics.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding MNLO: 
12
Total Market Value Held by ETFs: 
$3.49M
Total Market Capitalization: 
$119.00M
% of Market Cap. Held by ETFs: 
2.93%
 

Quotes delayed 20 minutes


Mergers & Acquisitions Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.